Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19868Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Kalaitzidis, R. | en |
| dc.contributor.author | Siamopoulos, K. C. | en |
| dc.date.accessioned | 2015-11-24T19:03:06Z | - |
| dc.date.available | 2015-11-24T19:03:06Z | - |
| dc.identifier.issn | 0028-2766 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19868 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antineoplastic Agents/*adverse effects | en |
| dc.subject | Calcium/blood | en |
| dc.subject | Calcium Metabolism Disorders/blood/chemically induced | en |
| dc.subject | Diphosphonates/*adverse effects | en |
| dc.subject | Electrolytes/*blood | en |
| dc.subject | Humans | en |
| dc.subject | Hypophosphatemia/*chemically induced | en |
| dc.subject | Magnesium/*blood | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Parathyroid Hormone/blood | en |
| dc.title | Multiple electrolyte abnormalities after pamidronate administration | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/9678436 | - |
| heal.identifier.secondary | http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000045059 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1998 | - |
| heal.abstract | Pamidronate constitutes a major advance in the treatment of tumor-associated hypercalcemia. However, transient electrolyte abnormalities have been reported after pamidronate administration. We describe here a patient with multiple myeloma and severe hypercalcemia who developed transient but significant electrolyte disturbances (mainly hypophosphatemia and hypomagnesemia) after a single dose of 90 mg of pamidronate, focusing on the underlying pathophysiological mechanisms. | en |
| heal.journalName | Nephron | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
